Ocuphire Pharma Results

APX3330 is Different Than Past Oral Failures in Retina APX3330 Targets Dual, Validated Retinal Disease Pathways with Favorable Human Safety Data Phase 1 TKIs ● Phase 2 VEGF MOA Oral failed due to dose limiting organ toxicity (e.g., hepatic) Plasma Kallikrein MOA targets inflammation Oral failed due to systemic toxicity (liver, cardiovascular monitoring²) ● Iptacopan Oral Complement inhibitor for GA Safety in Ph2 PNH study: headache (31% of patients) abdominal discomfort (15%) blood alkaline phosphatase increase (15%) cough (15%), oropharyngeal pain (15%) pyrexia (raised body temperature; 15%), and upper respiratory infection (15%) Bhatwadekar 2020 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265898/pdf/nihms-1594067.pdf Bryant 2009 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905712/pdf/nihms786745.pdf Ocuphire Eylea® and Lucentis label ARED & AREDS2 study PHARMA X Protein Kinase C VEGF MOA ● Phase 3 ● Phase 3 endpoint was visual acuity FDA requested more data for approval. Eli Lily did not pursue additional clinical trials Approved OTC Oral Successes Nutritional Supplements: Ocuvite®, PreserVision, EyePromise, Oral Vit C & E, Zn, Cu, Lutein, Zeaxanthin5 29

View entire presentation